Travere Therapeutics Inc
$ 46.74
-3.77%
10 Jun - close price
- Market Cap 4,516,665,000 USD
- Current Price $ 46.74
- High / Low $ 49.68 / 46.70
- Stock P/E N/A
- Book Value 1.07
- EPS -0.50
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.69 %
- 52 Week High 49.68
- 52 Week Low 13.88
About
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.
Analyst Target Price
$55.07
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-04 | 2026-02-19 | 2025-10-30 | 2025-08-06 | 2025-05-01 | 2025-02-20 | 2024-10-31 | 2024-08-01 | 2024-05-06 | 2024-02-15 | 2023-11-07 | 2023-08-03 |
| Reported EPS | -0.4 | 0.37 | 0.59 | 0.13 | -0.19 | -0.47 | -0.46 | -0.65 | -1.51 | -0.94 | 2.27 | -0.77 |
| Estimated EPS | -0.3 | -0.04 | -0.08 | 0.04 | -0.39 | -0.3786 | -0.54 | -0.72 | -0.79 | -0.92 | 0.04 | -0.93 |
| Surprise | -0.1 | 0.41 | 0.67 | 0.09 | 0.2 | -0.0914 | 0.08 | 0.07 | -0.72 | -0.02 | 2.23 | 0.16 |
| Surprise Percentage | -33.3333% | 1025% | 837.5% | 225% | 51.2821% | -24.1416% | 14.8148% | 9.7222% | -91.1392% | -2.1739% | 5575% | 17.2043% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.36 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TVTX
2026-06-11 20:39:35
Travere Therapeutics announced on June 11, 2026, that its Board of Directors' Compensation Committee granted inducement equity awards to six new employees. These grants consist of 32,000 restricted stock units (RSUs) and were made outside the company's 2018 Equity Incentive Plan as inducements under Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, dependent on continued employment.
2026-06-11 20:39:35
Travere Therapeutics announced inducement equity grants to six new employees on June 10, 2026, consisting of 32,000 restricted stock units (RSUs). These grants were made under Nasdaq Listing Rule 5635(c)(4) as material inducements for employment and will vest over four years.
2026-06-09 13:40:22
Travere Therapeutics (TVTX) stock recently hit a 52-week high of $48.70, reflecting a 216% increase over the past year. The company, with a $4.45 billion market cap and 96% revenue growth, is projected to become profitable this year with expected earnings of $1.75 per share, and analysts consider it undervalued. Recent positive developments include long-term clinical trial results for FILSPARI, a raised price target from H.C. Wainwright, and a new licensing agreement for civorebrutinib.
2026-06-08 17:10:32
This article identifies three U.S. stocks—Travere Therapeutics (TVTX), Goosehead Insurance (GSHD), and National Bank Holdings (NBHC)—that appear to be undervalued based on discounted cash flow analysis as of June 2026. Despite market drops, these companies show strong revenue or earnings growth potential, with projected discounts to their fair value. The analysis suggests these stocks could offer opportunities for investors seeking future growth.
2026-06-08 15:20:00
This article provides the transcript of Travere Therapeutics Inc's appearance at the Goldman Sachs Healthcare Conference. Eric Dube, President and CEO of Travere Therapeutics, discusses the company's background, focusing on its rare kidney disease commercial footprint, and answers questions from Goldman Sachs' Christina Yoon. The transcript highlights Travere's current activities and its emphasis on rare disease therapies.
2026-06-06 05:39:16
Peter Heerma, Chief Commercial Officer at Travere Therapeutics, sold 2,174 shares of common stock for $101,417 to cover tax obligations related to the vesting of performance restricted stock units. This transaction was not a discretionary trade but a mandatory "sell to cover." Following the vesting of 4,250 shares and the sale, Mr. Heerma now directly holds 140,684 shares of Travere Therapeutics.
